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Antonio Sampedro2,5, Juan Pasquau1,2, Carmen Hidalgo1,2, Javier Rosario1,2, Jose
Antonio Castilla2,4,6
1 Unidad de Enfermedades Infecciosas, Hospital Universitario Virgen de las Nieves, Granada, Spain,
2 Instituto de Investigación Biosanitaria de Granada (ibs.GRANADA), Granada, España, 3 UGC Medicina
Interna, Complejo Hospitalario de Jaén, Jaén, Spain, 4 Unidad de Reproducción, UGC Laboratorio Clı́nico y
UGC Obstetricia y Ginecologı́a, Hospital Universitario Virgen de las Nieves, Granada, Spain, 5 UGC
Microbiologı́a, Hospital Universitario Virgen de las Nieves, Granada, Spain, 6 Dpto. Anatomı́a y Embriologı́a
Humana, Facultad Medicina, Universidad de Granada, Granada, Spain
* malruz@ugr.es
Abstract
Many patients previously using darunavir/ritonavir (DRV/r) (800/100mg) have switched to
darunavir/cobicistat (DRV/C) (800/150 mg) either as part of triple therapy (ART) or as mono-
therapy with DRV (mDRV). The latter approach continues to be used in some countries for
patients receiving long-term treatment. However, to date, the behaviour of DRV/C in the
seminal compartment has not been analysed. This study explores how the combination
behaves in monotherapy, with respect to the control of viral load and seminal quality. To this
end, we studied 20 patients who were treated with mDRV/C after previous treatment with
mDRV/r for at least 24 weeks. A viral load control in seminal plasma similar to that published
in the literature was observed after 24 weeks of treatment with mDRV/C (viral load positivity
in 20% of patients). Similarly, semen quality was confirmed (70% normozoospermic) in
patients treated with this formulation, as has previously been reported for ART and mDRV/r.
The DRV levels measured in seminal plasma were above EC50, regardless of whether the
seminal viral load was positive or negative. We conclude that this mDRV/C co-formulation
behaves like mDRV/r in seminal plasma in terms of viral load control and semen quality.
Introduction
Sexual transmission is the main route of infection by human immunodeficiency virus type 1
(HIV-1). However, the risk of transmission via this route in patients who are positive for HIV-
1, who are receiving antiretroviral treatment with ART and who achieve undetectable plasma
viral load, provided there is correct adherence to the ART and the patient currently has no
other sexually transmitted disease, is close to zero (1:100,000) [1]. Similarly, transmission
between serodiscordant couples is significantly reduced when the seropositive member
receives effective ART [2,3].
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The semen quality of patients who are positive for HIV-1 and receiving treatment with
ART is known to be impaired [4,5]. A similar decrease has been observed in HIV-1 patients
who continue treatment with monotherapy with darunavir/ritonavir (mDRV/r) (800/100mg)
[6].
The noninferiority of monotherapy with protease inhibitors enhanced with ritonavir to
ART treatment has not been established, according to various meta-analyses [7,8] and system-
atic reviews [9]. Some of the studies included in these reviews were performed with DRV/r
[10–14]. However, in real life the use of enhanced DRV in monotherapy has become wide-
spread, due to its ease of application, the non-emergence of resistance, the maintenance of
undetectable viral load in most patients and the economic savings achieved [15,16]. Neverthe-
less, only the Gesida [17] and EACS [18] guidelines admit their use in certain circumstances,
while others, such as IAS [19] and DHHS [20], do not accept this approach.
Fewer studies have been conducted of mDRV/C (800/150 mg) [21,22]. The change from
DRV/r to DRV/C was motivated by the findings of the study GS-US-216-230 [23] in which the
efficacy and safety of the components were evaluated separately, mainly in naive patients, who
were administered initial ART with DRV/C + 2 ITIAN. The results obtained were similar to
those found in the ARTEMIS [24] and ODIN [25] studies.
Very few studies have examined the question of the seminal reservoir in patients receiving
monotherapy with protease inhibitors combined with ritonavir [6,26] and our review of the lit-
erature did not reveal any that explored the effect of the DRV/C combination in monotherapy,
with respect to viral load and to the semen quality of HIV-1 positive patients. To our knowl-
edge, neither have any studies been conducted to evaluate DRV levels in semen with this
combination.
The purpose of the present study is to evaluate semen quality, viral load and DRV levels in
seminal plasma among patients who initiated treatment with mDRV/r, who have received at
least six months’ treatment with mDRV/C and who present undetectable plasma viral load.
Materials and methods
Patients
Twenty HIV-1 patients aged over 18 years were drawn from those attending the outpatient
infections clinic at Virgen de las Nieves University Hospital (Granada, Spain). These patients
had received mDRV/C for 24 weeks and had previously been treated with mDRV/r for at least
24 weeks. All 20 patients had undetectable plasmatic viral load (<20 copies/mL) for a mini-
mum of six months before starting mDRV/C. The following exclusion criteria were applied:
the presence of sexually transmitted infection; any active disease at or during follow-up,
including acute or chronic hepatitis B; history of virological failure to regimens based on pro-
tease inhibitors; history of illness that could provoke a decrease in semen quality, except for
HIV infection itself; concomitant use of drugs with potential interaction with the prescribed
drugs; low adherence to the prescribed therapy.
From these 20 patients, eight were selected, four with positive viral load in semen and four
with negative viral load, to determine the concentration of DRV in seminal plasma (Fig 1). All
these patients provided signed informed consent to participate in the study, in accordance
with the principles of the Declaration of Helsinki. In addition, the study was approved by the
research ethics committee of Granada (CEI Granada). The patients’ data were codified to
maintain anonymity, as required by Spanish data protection laws.
The results for viral load and semen quality of these 20 patients, after treatment with
mDRV/C for 24 weeks, were compared with those obtained in a previous study performed in
21 patients who after receiving at least 24 weeks of ART, were given mDRV/r for 48 weeks [6].
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Of the 20 patients with mDRV/C, five had previously participated in this previous study of
mDRV/r [6] (Fig 1).
The patients received the normal medical visits, every four months. Adherence to the
medication was monitored by pharmacy report and by asking the patient during the medical
visit.
Variables analysed
Age, androgenic history, reproductive history, CD4+, CD4+ nadir, HIV viral load in seminal
fluid and plasma. The following semen quality parameters were analysed: viscosity, appear-
ance, liquefaction, volume, pH, sperm concentration, percentages of progressive and total
motility and of live sperm.
Semen analysis
All the samples were collected by masturbation, after 3–4 days of sexual abstinence, in the
andrology laboratory of the Human Reproduction Unit at the Virgen de las Nieves University
Hospital. On delivery of the sample to the laboratory, the following data were recorded: period
of sexual abstinence, whether any loss of the ejaculate had occurred, medication taken by the
participant, recent febrile processes, body mass index and recent extreme sports activity. All
the samples were analysed within one hour of collection, by a single highly-trained observer,
with more than ten years’ professional experience, who regularly participated in internal and
external controls. In this way, between-observer variation was avoided and the accuracy of the
study was ensured.
The ejaculates were analysed according to WHO recommendations [27] and the SEMQUA
2014 [28] international guidelines for semen quality studies. The concentrations of sperm and
of round cells were determined using a Neubauer Improved haemocytometer and positive dis-
placement pipettes. The total number of sperm cells was estimated by multiplying the concen-
tration by the seminal volume. The seminal volume was measured by weighing the sample.
Sperm motility was evaluated visually to calculate the percentage of sperm with progressive
motility. The vitality, the percentage of normal forms and the teratozoospermia index were
also calculated. The percentage of participants whose results were below the lower limit of the
WHO 2010 reference values for sperm parameters was determined.
Fig 1. Patients included in different procedures of the study according to the seminal viral load.
https://doi.org/10.1371/journal.pone.0196257.g001
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Determination of viral load in seminal fluid
The viral load in seminal fluid was determined after centrifugation at 3000g for 15 min. The
technique used to quantify HIV-1 RNA in the final processed sample was that of real-time
PCR, an adaptation of the HIV-1 COBAS Ampliprep/Taqman assay version 2.0 (Roche).
Determination of DRV levels in seminal fluid
DRV, Ctrough and seminal plasma concentrations were quantified using a modified and vali-
dated liquid chromatography with a tandem mass spectrometry method [29]. The participants
were instructed to take their drugs in the morning after a standard breakfast and to record the
time when they had taken the medication the previous day. The semen samples were collected
24 ±1 h after the previous mDRV/C dose. Seminal plasma was separated by centrifugation and
stored at -80˚C until tested. The standard curves were highly linear over the range of 10−1000
ng/mL in seminal plasma. The intra- and interassay coefficient of variation were<15% for
DRV in seminal plasma.
Statistical analysis
A descriptive analysis was performed to obtain measures of central tendency and dispersion
for the numerical variables, and absolute and relative frequencies for the categorical ones. The
Shapiro-Wilks test of normality was applied. Differences between the groups were determined
by a bivariate analysis, using the non-parametric Mann-Whitney test for the numerical vari-
ables and Pearson’s chi-square test or Fisher’s exact test for the categorical ones. The level of
significance considered for all analyses was p<0.05. The statistical analysis was performed
using IBM SPSS Statistics 19 software.
Results
General characteristics of the patients included in the study
The mean age was 47.5 years (SD: 6.8), the mean CD4+ T cell count was 882 cell/μL (SD:316.8)
and the mean nadir CD4+ T cell count was 277 cell/μL (SD:191.5).
Viral load in seminal fluid
HIV-PCR in the seminal fluid was analysed for all 20 patients; four (20%) were positive (>20
copies/mL), with a range of 21–1070 copies/mL.
Semen quality
The data on semen quality for patients on monotherapy are summarised in Tables 1 and 2.
Only 14 of the 20 samples (70%) patients presented higher sperm values than the lower limit of
the WHO 2010 reference values. The alterations most frequently observed were oligoastenos-
permia and oligoastenoteratospermia (Table 2). No significant differences were observed in
the sperm parameters analysed in patients treated with ART and mDRV/r [6] with respect to
the values obtained in the present study with mDRV/C (Table 2).
Of the patients included in both studies (n = 5) three had no positive viral load in seminal
plasma with no monotherapy regimen, one had viral load in both regimens and one had posi-
tive viral load with mDRV/C and negative viral load with mDRV/r (data not shown).
Comparison of viral load positivity of the seminal plasma among patients with mDRV/C
(20%) with respect to those with mDRV/r (3%) revealed no significant differences
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(p = 0.0656). Neither were any differences observed regarding the average number of copies
(382/mL vs. 132/mL, p = 0.480).
Semen quality was normal in 16/28 (57.1%) of patients in ART, in 13/21 (61.9%) of those in
mDRV/r and in 14/20 (70%) of those in mDRV/C. No significant differences were observed in
comparisons of ART with mDRV/r (p = 0.7372), ART with mDRV/C (p = 0.3643) or mDRV/r
with mDRV/C (p = 0.5848).
The median concentration of DRV in seminal fluid was 489.4 ng/mL (range: 204.4–1889.2
ng/mL), with 680.5 ng/mL in the four patients with positive viral load and 405.9 ng/mL in the
four with negative viral load (p = 0.149) (data from individual patients not shown).
Discussion
To our knowledge, this study is the first to analyse semen quality and viral load in HIV+ men
treated with mDRV/C. To date, all seminal plasma studies of monotherapy in HIV+ patients
have been performed using ritonavir, at low doses, as a pharmacokinetic enhancer. The mDRV/
C treatment combination was adopted because of the potency of the DRV/C [23] combination,
and experience in the use of monotherapy in conjunction with protease inhibitors [15].
In our study, 20% of the patients treated with mDRV/C had a negative plasma viral load
and a positive seminal viral load, a similar proportion to that observed in other studies of
Table 2. Semen quality in patients receiving mDRV/r [6] and mDRV/C.








mDRV/r: monotherapy with darunavir/ritonavir; mDRV/C: monotherapy with darunavir/cobicistat; Not significant
https://doi.org/10.1371/journal.pone.0196257.t002
Table 1. Seminal fluid values of the 20 patients treated with mDRV/C compared with the results of 21 patients
treated initially with ART and then with mDRV/r [6].
ART n = 21 [6] mDRV/r n = 21 [6] mDRV/C n = 20
Volume; Ml 2.3(1.7–3) 1.9(1.5–3.4) 2.5(1.5–3.5)
PH 7.5(7.2–7.5) 7.5(7.2–7.7) 7.6(7.5–7.7)
Sperm; x106/mL 59(20.5–141.5) 39(14–109.5) 43(13.3–99)
Round cells; x106/mL 3(1–8) 2(1.1–3.8) 2(1–6)
Total sperm count; x106 154(42–319.5) 132(31.8–259.5) 122.8(26.4–251.2)
Progressive motility; % 45(32.5–63) 52.5(40–65) 50(41–64)
Total motility; % 60(42–70) 60(45–79) 64(60–81)
Normal form; % 5(3–6) 4(4–7.5) 6(5–9)
Live sperm;% 88(79.5–90.5) 86.5(80.5–90.8) 85(79–89)
Teratospermia index 1.3(1.2–1.4) 1.3(1.2–1.4) 1.3(1.2–1.5)
Median (Q1-Q3); ART: Triple therapy; mDRV/r: monotherapy with darunavir/ritonavir; mDRV/C: monotherapy
with darunavir/cobicistat; Not significant
https://doi.org/10.1371/journal.pone.0196257.t001
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patients treated with ART [26,30–32] or protease inhibitors/r [33]. However, our findings dif-
fer from those obtained by some authors [34,35], who did not detect any patient with a positive
seminal viral load. These discrepancies may be due to the HIV-RNA detection technique used,
since the detection limits described by the latter authors were much higher (<150 copies/mL
and<200 copies/mL, respectively) than those used in our study (<20 copies/mL).
Furthermore, the viral load of RNA-HIV found in the seminal plasma of patients treated
with mDRV/C presented values similar to those observed by other authors with 270–1345 cop-
ies/Ml [33], with 31–1445 copies/Ml [26] or with 35–1210 copies/Ml. [6] One patient in the cur-
rent study presented a positive viral load in seminal plasma after 24 weeks with mDRV/C. This
patient had previously presented a positive viral load when treated with mDRV/r for 48 weeks.
The levels of DRV observed in seminal fluid are similar to those found by other authors in
patients with similar treatments [33,36]. The latter studies reported that the free fraction of
DRV in semen ranged from 7–20% of that observed in blood plasma. The free fraction of the
drug is considered the only effective fraction available for tissue diffusion or penetration [33].
In view of the low percentage found of positive viral load with mDRV/C, we believe that this
drug is as safe and effective as ART, despite the low penetration of DRV within the male genital
tract. The capacity of a drug to enter the male genital compartment depends on a number of
factors, including molecular size, lipophilicity, degree of ionisation, plasma protein binding
and whether or not the drug is a substrate for efflux transporters [37]. In general, PIs present
various unfavourable characteristics, which tend to impede passive diffusion [36,38]. Like
most PIs, DRV is highly bound to plasma proteins (95%), with a small fraction (5%) of
unbound drug available to penetrate the male genital tract.
The levels of DRV in the seminal plasma of the eight patients in our study were above EC50
[36] and EC90 [39], independently of whether the viral load in semen was positive or negative.
Although we are unaware of previous studies of seminal plasma concentrations with mDRV/
C, with which to compare our results, it has been reported that Cmin in blood plasma is ade-
quate even in the presence of a positive viral load in seminal plasma [40]. Other authors have
also observed an absence of relationship between ART levels and viral load [41].
The standardisation of seminal quality studies is of crucial importance if valid conclusions
are to be obtained. Our group participated in the development of the SEMQUA recommenda-
tions for the design and evaluation of seminal quality studies [28] and the present analysis is in
line with these recommendations.
Regarding seminal quality, no significant improvement was observed with mDRV/C with
respect to mDRV/r or ART, with normozoospermic patients accounting for 70%, 62% and
57%, respectively, of the total. However, the observed pattern of improving seminal quality in
patients who received mDRV/r and mDRV/C may be due to the fact that the nucleoside ana-
logues received by patients in antiretroviral treatment are associated with greater mitochon-
drial toxicity [42,43].
The main limitation of this study is the limited number of cases examined, regarding both
viral load and seminal quality, and the number of determinations of DRV concentration in
seminal plasma. Accordingly, our findings are subject to confirmation by subsequent studies
with a larger number of participants. A second limitation is the centrifugation step performed
to separate the seminal plasma samples. Unrecognized cell contamination of the seminal
plasma samples could confound our results and might result in inhibition of PCR and false
HIV-RNA measurements, despite the centrifugation step. We believe this scenario is unlikely,
however, as we observed no inhibition of PCR in the 20 samples analysed. Furthermore, the
proportion of HIV-1 infected men with sustained suppressed HIV-1 RNA in blood plasma
who have detectable levels of HIV-1 RNA in seminal plasma, as commented above, was similar
to that observed by other authors using a different centrifugation protocol [26,30–33].
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Despite its limitations, the present study provides suggestive evidence that in HIV-1
patients treated with mDRV/C, viral load and seminal quality results are similar to those
obtained in the previous study in this respect [6], both in the treatment with ART and in that
with mDRV/r. These results need to be confirmed by a study with a larger number of patients.
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